Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
upgraded at Citigroup from Sell to Buy. $10 price target. Sales should hold up better than in other cycles.
rated new Neutral at UBS. $25 price target. Stock is already pricing in the fact that the company is gaining market share.
downgraded at Wells to Market Perform. Valuation call, as the stock is up 39% since September.
( BEXP) upgraded at BMO from Underperform to Market Perform. Valuation call, based on a $26 price target.
rated new Equal-weight at Morgan Stanley. Core transport market remains soft.
upgraded at Barclays to Overweight from Equal Weight. Strong fundamentals in optical equipment markets, Barclays said. Price target raised to $18 from $16.
( CPX) rated new Neutral at Goldman. Valuation call, based on a $24 price target.
upgraded at Jefferies from Hold to Buy. $20 price target. Company should maintain from stable market share at AAPL and benefit from higher prices.
downgraded at Morgan Stanley to Equal-weight. Valuation call, based on an $80 price target.
Green Mountain Coffee Roasters
upgraded at BofA/Merrill to Buy from Underperform as adoption rates are progressing better than expected. Price target surged to $44 from $30.
rated new Outperform at BMO. Coverage of HRL was started with an Outperform rating. $57 price target. Company should deliver consistent, above-average earnings growth.
( MEE) downgraded at FBR from Outperform to Market Perform. Valuation call, based on a $55 price target.
upgraded at JP Morgan from Neutral to Overweight. New analyst also has a $155 price target. Company should benefit from higher potash prices.
rated new Sell at Goldman. $21 price target. Competition could increase in the pressure pumping market in the new year.
rated new Buy at Goldman. Company was also added to the Conviction list. Xifaxan antibiotic could top $1 billion of annual sales by 2015. $58 price target.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $56 price target. Company should see better NAND pricing in the first half of the year.
upgraded at BofA/Merrill to Neutral from Underperform. We expect SO to resume its 6% long term growth trajectory in 2011 and expect and approval of the reasonable GA settlement, Bank of America/Merrill Lynch said. Price target increased to $39 from $37.
upgraded at Citigroup from Hold to Buy. $17 price target. Company is positioned well for the second leg of the cycle.
upgraded at Morgan Stanley from Equal-weight to Overweight. $21 price target. December analyst meeting should be a positive catalyst.
This article was written by a staff member of TheStreet.